Slowing the HIV and HCV epidemic for people who inject drugs (WP1578)

Image: ozgurcankaya

People who inject drugs (PWID) are at much higher risk of HIV, Hepatitis C (HCV) and HIV/HCV co-infection than the general population. Of the estimated 12 million PWID globally, approximately 14% are living with HIV, 52% are living with HCV. The vast majority of PWID living with HIV are co-infected with HCV (82.4%).

Though significant progress has been made to curb these epidemics, PWID remain particularly susceptible to new infections, co-infection, chronic disease and mortality. In 2011 the UN set a target to reduce new infections among PWID by 50% by 2015. However, new HIV infections in PWID increased by 33% between 2011 and 2014. In high and middle income countries, PWID account for most of new HCV infections and existing HCV cases. Globally, PWID represent 23% of new HCV infections and account for 31% of HCV related deaths. Additionally, many countries around the world are experiencing rising overdoses and drug-related deaths as opioid addiction and injection drug use continue to increase.

Despite this, PWID continue to face significant social and structural barriers to healthcare that are rooted in stigma, discrimination and criminalisation. According to UNAIDS, over half of PWID will be incarcerated at some point in their lives. While in prison, PWID are further exposed to HIV and HCV through continued, unsafe drug use.

The internationally agreed Sustainable Development Goals (2015) set a target to “strengthen the prevention and treatment of substance abuse, including narcotic drug abuse and harmful use of alcohol” (SDG 3).

Many proven tools and strategies to improve PWID’s health and lives already exist. The United Nations Office on Drugs and Crime (UNODC), the World Health Organization (WHO) and UNAIDS support expansion of evidence-based, harm reduction interventions to reduce vulnerability to infectious diseases and improve uptake of health and social services. These include: needle and syringe programmes, opioid substitution therapy and increased access to HIV/AIDS testing and treatment and overdose prevention (eg naloxone).

Integrating harm reduction, health and social services to address drug use and infectious diseases, including HIV and HCV is recommended by UNODC, WHO and UNAIDS. Service integration has shown to improve adherence to antiretroviral therapy and HCV treatment, and overall health outcomes. Historically, support for these programmes has been tied to HIV funding. However, increased momentum around global HCV goals could expand support for integrated PWID treatment and care.

Notwithstanding efforts to address HIV and HCV, stakeholders remain concerned that global goals have not generated the support and funding needed to serve PWID. Proven interventions have not been brought to scale and life-saving medicines are still difficult to access due to prohibitive laws and policies.

According to the ‘2016 Global State of Harm Reduction Report’, out of 158 countries and territories where injection drug use has been reported, 68 still have no needle and syringe programmes and 78 do not provide opioid substitution therapy.

There is also growing concern over reduced funding from global donors for harm reduction programmes, particularly in middle income countries where many PWID live. New commitments and policies that address these access challenges through a human rights lens will be key to reach PWID effectively and slow the HIV and HCV epidemics. Whilst funding for HIV/HCV co-infection has been made available through traditional HIV funders (Global Fund, UNITAID, USAID/CDC) funding for HCV treatment and care remains a significant challenge.

Aims and objectives

This meeting will convene high-level stakeholders including policymakers, researchers, clinicians, advocates, implementers and industry representatives, to discuss how to reach PWID with HIV and HCV prevention, treatment and care measures.

Specifically, discussion will aim to:

  • Identify effective strategies to overcome barriers to providing PWID with health care, including reaching incarcerated PWID populations
  • Share lessons from countries that have successfully carried out effective PWID programmes
  • Look for synergies to expand integrated service delivery models for PWID
  • Recognise and strengthen the role of community networks of PWID in the response
  • Determine how to better coordinate across sectors to improve data collection, surveillance and research
  • Build the investment case for international donors in evidence-based solutions
  • Explore how the global frameworks, such as UNAIDS Fast-Track Strategy to End the AIDS Epidemic by 2030, WHO Global Health Sector Strategies for HIV/AIDS and Viral Hepatitis, 2016 UNGASS on the World Drug Problem Outcome Document and Sustainable Development Goals commitments to ‘leave no one behind’, can be leveraged for greater political and financial support for PWID programmes and policies
  • Create a roadmap of opportunities, milestones and actions in the lead-up to the High Level Meeting on the world drug problem due to take place in March 2019

Mon 26 - Wed 28 February, 2018

Wiston House

Wilton Park
Wiston House, Steyning
West Sussex
BN44 3DZ
+44 (0) 1903 815 020
For more information see Your stay at Wilton Park

View map

Event no:
Sustainable development and the environment
diseases, drugs, global health, hcv, health, healthcare, Hepatitis C, hiv, pwid, SDGs
How to attend:
This event is by invite only.


Robin Hart: Programme Director

Biography and other events

Lisa Elvy: Project Manager

T: +44 (0) 1903 817777
F: +44 (0) 1903 816373
E: lisa.elvy@wiltonpark.org.uk


Our key sponsor(s) for this event: